重新审视代谢功能障碍相关脂肪性肝病中的肥胖悖论:纵向轨迹分析揭示随时间变化的死亡风险
该研究基于三个大型人群队列(NHANES III n=2190、NHANES 1999-2018 n=5210、UK Biobank n=8962),采用限制性立方样条和潜在类别轨迹模型分析BMI轨迹与MASLD患者死亡率的关联。结果显示,成年中晚期或诊断后BMI>30 kg/m2与全因死亡率降低相关(P<.001),但早期成年较高BMI及持续肥胖轨迹(HR 1.79, 95%CI 1.10-2.89)与死亡率升高相关。结论认为肥胖与MASLD结局的关联具有异质性,取决于肥胖暴露时机,长期维持非肥胖状态与较低的全因死亡率相关。
要点
- 中晚年或MASLD诊断后BMI>30与全因死亡率降低相关(P<.001)。
- 持续肥胖轨迹(HR 1.79)和BMI快速增加轨迹(HR 1.93)与死亡率显著升高相关。
- 成年期维持非肥胖状态与较低的全因死亡率相关。
核心结论
- 肥胖与MASLD结局的关联具有异质性,取决于肥胖暴露时机。
- 长期BMI轨迹分析提示肥胖并不赋予MASLD生存优势,成年期维持非肥胖状态与较低全因死亡率相关。
研究设计与样本
- 基于三个大型人群MASLD队列:NHANES III(n=2190)、NHANES 1999-2018(n=5210)和UK Biobank(n=8962)。
- 采用多变量调整限制性立方样条模型评估不同成年/疾病阶段BMI与死亡率的剂量反应关联,并用潜在类别轨迹模型识别长期BMI模式。
主要发现
- 成年中晚期或MASLD诊断后BMI>30 kg/m2与全因死亡率降低相关(P<.001)。
- 早期成年较高BMI与死亡率升高相关(P<.001)。
- 诊断前BMI与全因死亡率呈U型关联,与癌症特异性死亡率呈J型关联。
- 持续非肥胖轨迹组全因死亡风险低;持续肥胖轨迹(HR 1.79, 95%CI 1.10-2.89)和BMI快速增加轨迹(HR 1.93, 95%CI 1.03-3.64)与显著更高的死亡率相关。
- 肥胖发病较早的轨迹组死亡风险趋于更高;40岁前暴露肥胖的轨迹组晚年BMI趋于下降,且成年期BMI下降与死亡率增加相关(P<.001)。
临床怎么用
- 评估MASLD患者死亡风险时需考虑肥胖暴露时机和长期BMI轨迹,而非仅依赖单次BMI。
- 对于持续肥胖或BMI快速增加的患者,应加强代谢风险管理。
- 成年期维持非肥胖状态可能有助于降低全因死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Obesity is a key driver of metabolic dysfunction-associated steatotic liver disease (MASLD). Paradoxically, obese patients with MASLD often exhibit better survival than their nonobese counterparts. This study investigates the "obesity-survival paradox" using longitudinal body mass index (BMI) data. METHODS: We analyzed 3 large population-based MASLD cohorts, including National Health and Nutrition Examination Survey (NHANES) III (n = 2190), NHANES 1999-2018 (n = 5210), and UK Biobank (n = 8962). We assessed the dose-response associations of BMI at different stages of adulthood/disease with mortality using multivariable-adjusted restricted cubic spline models. Latent class trajectory modeling identified distinct clusters of long-term BMI patterns. RESULTS: BMI above 30 kg/m2 in mid-to-late adulthood or after MASLD diagnosis was associated with decreased overall mortality (P < .001), indicating an obesity-survival benefit. Conversely, higher early-adulthood BMI was associated with increased mortality (P < .001). Pre-diagnostic BMI displayed U-shaped and J-shaped associations with all-cause and cancer-specific mortality, respectively. Trajectory analyses indicated that the cluster with persistent nonobesity throughout adulthood had a low overall mortality risk, whereas persistent obesity (hazard ratio, 1.79; 95% confidence interval, 1.10-2.89) and rapid BMI increase (hazard ratio, 1.93; 95% confidence interval, 1.03-3.64) were associated with significantly higher mortality. Clusters with earlier obesity onset tended toward higher mortality. Among clusters exposed to obesity before age 40, BMI had a tendency to decline during later life, and such BMI declines across adulthood were associated with increased mortality (P < .001). CONCLUSIONS: This study demonstrates that the association between obesity and MASLD outcomes is heterogeneous and depends on the timing of obesity exposure. Long-term BMI trajectory analysis suggests that obesity does not confer a survival advantage in MASLD, whereas maintaining nonobese status throughout adulthood is associated with lower overall mortality.
引用
- Sun Z, Li J, Yu X, et al. Revisiting the Obesity Paradox in Metabolic Dysfunction-Associated Steatotic Liver Disease: Longitudinal Trajectory Analysis Reveals Time-Varying Mortality Risks. Clin Gastroenterol Hepatol. 2026. PMID: 41643801. doi:10.1016/j.cgh.2026.01.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。